Biogen’s other Alzheimer’s drug fails in late-stage trial

Less than two weeks after the historic approval of Aduhelm, a different Alzheimer’s disease drug developed by Biogen Inc. (Nasdaq: BIIB) has failed in a late-stage clinical trial.